Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
First-Line PFS - ALECENSA® (alectinib)
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program | Oncotarget
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program | Oncotarget
Frontiers | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence - Wang - 2022 - Cancer Medicine - Wiley Online Library
Cancers | Free Full-Text | Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
A) Kaplan-Meier curve of progression-free survival (PFS) in the... | Download Scientific Diagram
EGFR- and ALK-targeted treatment: present and future - memoinOncology
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
Potent treatment options in ALK– and MET-positive disease - memoinOncology
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer☆ - ESMO Open
Stephen V Liu, MD on Twitter: "#ESMOAsia22 Survival is favoring alectinib for #ALK NSCLC over crizotinib, but not yet significant. Medians not reached and OS HR 0.60 overall with OS HR 0.40
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer | Semantic Scholar
Changing Treatment Paradigm for ALK-Positive Lung Cancer - ILCN.org (ILCN/WCLC)
Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up | JACC: CardioOncology
Cancers | Free Full-Text | Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
ALK-positive NSCLC: updates on crizotinib and alectinib - memoinOncology
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Diagnostics | Free Full-Text | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
